Please ensure Javascript is enabled for purposes of website accessibility

The Highest-Rated Biotech Stocks

By Dan Dzombak - Updated Apr 6, 2017 at 5:51PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

These stocks were given the highest marks in their industry by our community of investors.

Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, the 10 stocks below are the highest rated in the biotech industry.

CAPS contains more than just the crowd's opinions. The votes of CAPS' best-performing members, known as All-Stars, count more in shaping each company's rating than do the picks of their poorer-performing peers. That way, investors can intelligently use members' collective wisdom to make better decisions.

The highest-rated biotech stock is...
Looking at the aggregate data, we see that our community rates Repligen (Nasdaq: RGEN) above the rest, and for good reason. As CAPS All-Star zzlangerhans wrote:

Repligen gets a green thumb for flirting with the one year low on lousy results of their phase III trial of secretin as an adjunct for pancreatic MRI. Disappointing I guess, but I don't know about a 20% haircut on a stock already down 15% from recent highs. The company will likely continue to maintain cash flows even through anemic 5M quarterly revenues and lazy spending on the phase IIb trial of (yawn) uridine for bipolar disorder. Is this the most boring baby biotech around? Possibly.

Here are the rest of the 10 highest-rated companies in the industry along with their CAPS rating:



CAPS Rating (out of 5)

Market Cap (in millions)

1 Repligen ***** $104
2 Myrexis ***** $70
3 Astex Pharmaceuticals (Nasdaq: ASTX) ***** $181
4 Aeterna Zentaris (Nasdaq: AEZS) ***** $153
5 Emergent BioSolutions (NYSE: EBS) ***** $644
6 Gilead Sciences (Nasdaq: GILD) **** $30,586
7 Progenics Pharmaceuticals **** $208
8 Spectrum Pharmaceuticals (Nasdaq: SPPI) **** $673
9 BioMarin Pharmaceutical **** $3,791
10 PDL BioPharma (Nasdaq: PDLI) **** $853

Source: Motley Fool CAPS as of Nov. 7, 2011.

Use the table as a first step to help generate ideas for further research. Having a watchlist of promising companies is a great place to start. We can help you keep tabs on these beloved companies with My Watchlist, our free, personalized stock tracking service. Click here to start now.

Fool contributor Dan Dzombak can be found on his Twitter account: @dandzombak. Click here to see his holdings and a short bio.

Motley Fool newsletter services have recommended buying shares of Gilead Sciences, Emergent BioSolutions, and BioMarin Pharmaceutical. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Aeterna Zentaris Inc. Stock Quote
Aeterna Zentaris Inc.
$4.99 (0.40%) $0.02
PDL BioPharma, Inc. Stock Quote
PDL BioPharma, Inc.
Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
$62.96 (0.82%) $0.51
Emergent BioSolutions Inc. Stock Quote
Emergent BioSolutions Inc.
$30.50 (2.04%) $0.61
Spectrum Pharmaceuticals, Inc. Stock Quote
Spectrum Pharmaceuticals, Inc.
$1.36 (12.40%) $0.15
Repligen Corporation Stock Quote
Repligen Corporation
$251.35 (1.97%) $4.86

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/15/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.